JPMorgan analyst Tessa Romero lowered the firm’s price target on Biohaven (BHVN) to $55 from $68 and keeps an Overweight rating on the shares. The firm updated its model following recent developments for Biohaven. It now models a U.S. launch for troriluzole in spinocerebellar ataxia beginning in Q4 instead of Q3 following the DDA action date extension. JPMorgan also removed revenue contributions from BHV-2100 for acute migraine following the completion of the proof-of-concept Phase 2 trial with no efficacy signal detected.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Bexorg announces multi-program research collaboration with Biohaven
- Biohaven Ltd. Highlights Strategic Focus in Investor Presentation
- 3 Best Stocks to Buy Now, 6/2/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 5/30/2025, According to Top Analysts
- Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments